Recent Review Articles

Boikos C. et al. Safety and effectiveness of neuraminidase inhibitors in situations of pandemic and/or novel/variant influenza: a systematic review of the literature, 2009-15. J Antimicrob Chemother. 2017 Feb 13.
Abstract

Review Articles - Influenza Antivirals
2012 - February 2017

Atkins C. et al. Screening methods for influenza antiviral drug discovery. Expert Opin Drug Discov. 2012 May;7(5):429-38.
Abstract

Alves Galvão M.G. et al. Amantadine and rimantadine for influenza A in children and the elderly. Cochrane Database Syst Rev. 2012
Full text

Balasingam S, Wilder-Smith A. Randomized controlled trials for influenza drugs and vaccines: a review of controlled human infection studies.Int J Infect Dis. 2016 May 18. pii: S1201-9712(16)31056-6.
Full text

Barik S. New treatments for influenza. BMC Med. 2012 Sep 13;10:104.
Full text

Beck CR. et al. Neuraminidase inhibitors for influenza: a review and public health perspective in the aftermath of the 2009 pandemic. Influenza Other Respi Viruses 2013 Jan;7 Suppl 1:14-24.
Full text

Boikos C. et al. Safety and effectiveness of neuraminidase inhibitors in situations of pandemic and/or novel/variant influenza: a systematic review of the literature, 2009-15. J Antimicrob Chemother. 2017 Feb 13.
Abstract

Burnham AJ. at al. Neuraminidase inhibitors for influenza B virus infection: Efficacy and resistance. Antiviral Res. 2013 Sep 4. pii: S0166-3542(13)00243-X.
Abstract

Chairat K. et al. Pharmacokinetic properties of anti-influenza neuraminidase inhibitors. J Clin Pharmacol. 2013 Feb;53(2):119-39.
Abstract

Chamni S, De-Eknamkul W. Recent progress and challenges in the discovery of new neuraminidase inhibitors. Expert Opin Ther Pat. 2013 Apr;23(4):409-23.
Abstract

Chintakrindi A, D'souza C, Kanyalkar M. Rational development of neuraminidase inhibitor as novel anti-flu drug. Mini Rev Med Chem. 2012 Oct;12(12):1273-81
Abstract

Choe YJ. et al. Antiviral treatment of influenza in South Korea. Expert Rev Anti Infect Ther. 2015 Apr 3:1-9.
Abstract

Costa S.S. et al. Flavonoids in the therapy and prophylaxis of flu: a patent review. Expert Opin Ther Pat. 2012 Oct;22(10):1111-21. Epub 2012 Sep 13.
Abstract

Dixit R. et al. Emergence of oseltamivir resistance: control and management of influenza before, during and after the pandemic. Infect Disord Drug Targets. 2013 Feb;13(1):34-45.
Abstract

Dobson J. et al. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet. 2015 Jan 29. pii: S0140-6736(14)62449-1.
Abstract

Du J, Cross TA, Zhou HX. Recent progress in structure-based anti-influenza drug design. Drug Discov Today. 2012 Oct;17(19-20):1111-20.
Full text

Dunn AG. et al. Financial conflicts of interest and conclusions about neuraminidase inhibitors for influenza: an analysis of systematic reviews. Ann Intern Med. 2014 Oct 7;161(7):513-8.
Abstract

Dunning J. et al. Antiviral combinations for severe influenza. Lancet Infect Dis. 2014 Sep 8. pii: S1473-3099(14)70821-7.
Abstract

Ebell MH, Call M, Shinholser J. Effectiveness of oseltamivir in adults: a meta-analysis of published and unpublished clinical trials. Fam Pract. 2013 Apr;30(2):125-33.
Abstract

Farrukee R, Mosse J, Hurt AC. Review of the clinical effectiveness of the neuraminidase inhibitors against influenza B viruses. Expert Rev Anti Infect Ther. 2013 Nov;11(11):1135-45.
Abstract

Feng E. et al. Recent advances in neuraminidase inhibitor development as anti-influenza drugs. ChemMedChem. 2012 Sep;7(9):1527-36.
Abstract

Freemantle N. et al. Oseltamivir: the real world data. BMJ. 2014 Apr 9;348:g2371.
Abstract

Govorkova EA, McCullers JA. Therapeutics against influenza. Curr Top Microbiol Immunol. 2013;370:273-300.
Abstract and references

Govorkova EA. Consequences of resistance: in vitro fitness, in vivo infectivity, and transmissibility of oseltamivir-resistant influenza A viruses. Influenza Other Respi Viruses 2013 Jan;7 Suppl 1:50-7.
Full text

Hama R, Bennett CL. The mechanisms of sudden-onset type adverse reactions to oseltamivir. Acta Neurol Scand. 2016 Jun 30.
Full text

Hata A. et al. Safety and efficacy of peramivir for influenza treatment. Drug Des Devel Ther. 2014 Oct 24;8:2017-2038.
Full text

Hayden FG. Newer influenza antivirals, biotherapeutics and combinations. Influenza Other Respi Viruses 2013 Jan;7 Suppl 1:63-75.
Abstract

Hayden FG. Experimental human influenza: observations from studies of influenza antivirals. Antivir Ther. 2012;17(1 Pt B):133-41.
Full text

Heneghan CJ. et al. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014 Apr 9;348:g2547.
Full text

Heneghan CJ. et al. Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. Health Technol Assess. 2016 May;20(42):1-242.
Full text 

Hsieh IN, Hartshorn KL. The Role of Antimicrobial Peptides in Influenza Virus Infection and Their Potential as Antiviral and Immunomodulatory Therapy. Pharmaceuticals (Basel). 2016 Sep 6;9(3). pii: E53.
Full text

Hsu J. et al. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med. 2012 Apr 3;156(7):512-24.
Abstract

Huang L. et al. [Neuraminidase inhibitors resistance in influenza viruses and the related mechanisms]. [Article in Chinese] Bing Du Xue Bao. 2012 Sep;28(5):572-6.
Abstract

Hurt AC. The epidemiology and spread of drug resistant human influenza viruses. Curr Opin Virol. 2014 May 24;8C:22-29.
Abstract

Hurt A.C. et al. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect Dis. 2012 Mar;12(3):240-8.
Abstract

 

Ide K. Anti-Influenza Virus Effects of Catechins: A Molecular and Clinical Review. Curr Med Chem. 2016 Nov 22.
Abstract

Ide K, Yamada H, Kawasaki Y. Effect of gargling with tea and ingredients of tea on the prevention of influenza infection: a meta-analysis. BMC Public Health. 2016 May 12;16(1):396.
Full text

Ison MG. Optimizing antiviral therapy for influenza: understanding the evidence.Expert Rev Anti Infect Ther. 2015 Feb 19:1-9
Abstract

Ison MG. Clinical use of approved influenza antivirals: therapy and prophylaxis. Influenza Other Respi Viruses 2013 Jan;7 Suppl 1:7-13.
Full text

Jagannath VA. et al. Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis. Cochrane Database Syst Rev. 2016 Feb 24;2:CD008139.
Full text

Jefferson T. et al. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014 Apr 9;348:g2545.
Full text

Jefferson T. et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2012 Jan 18;1:CD008965.
Full text

Karadag-Oncel E, Ceyhan M. Oseltamivir in neonates, infants and young children: a focus on clinical pharmacology. Infect Disord Drug Targets. 2013 Feb;13(1):15-24.
Abstract

Laplante J, St George K. Antiviral Resistance in Influenza Viruses: Laboratory Testing. Clin Lab Med. 2014 Jun;34(2):387-408.
Abstract

Li TC, Chan MC, Lee N. Clinical Implications of Antiviral Resistance in Influenza. Viruses. 2015 Sep 14;7(9):4929-44.
Full text

Loregian A et al. Antiviral strategies against influenza virus: towards new therapeutic approaches. Cell Mol Life Sci. 2014 Oct;71(19):3659-83.
Abstract

Maxwell-Scott H. et al. Antiviral therapy for the treatment and prophylaxis of influenza. Br J Hosp Med (Lond). 2013 Oct;74(10):C157-60.
Abstract

McKimm-Breschkin JL. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza Other Respi Viruses 2013 Jan;7 Suppl 1:25-36.
Full text

McKimm-Breschkin JL, Fry AM. Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses. Antiviral Res. 2016 Feb 9;129:21-38.
Abstract

McLaughlin MM, Skoglund EW, Ison MG. Peramivir : an intravenous neuraminidase inhibitor. Expert Opin Pharmacother. 2015 Aug;16(12):1889-900.
Abstract

McMahon A, Martin-Loeches I. The pharmacological management of severe influenza infection - 'existing and emerging therapies'. Expert Rev Clin Pharmacol. 2016 Nov 25:1-15.
Abstract

Michiels B. et al. The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews. PLoS One. 2013;8(4):e60348.
Full text

Miki M, Watanabe A. [New antiviral agents of influenza]. [Article in Japanese] Nihon Rinsho. 2012 Apr;70(4):649-54.
Abstract

Mizumoto K, Nishiura H, Yamamoto T. Effectiveness of antiviral prophylaxis coupled with contact tracing in reducing the transmission of the influenza A (H1N1-2009): a systematic review. Theor Biol Med Model. 2013 Jan 16;10:4.
Full text

Müller K.H. et al. Emerging cellular targets for influenza antiviral agents. Trends Pharmacol Sci. 2012 Feb;33(2):89-99.
Abstract

Muthuri SG. et al. Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an IPD meta-analysis. Influenza Other Respir Viruses. 2015 Nov 25.
Full text

Muthuri S.G. et al. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. J Infect Dis. 2013 Feb 15;207(4):553-63.
Full text

Naesens L, Stevaert A, Vanderlinden E. Antiviral therapies on the horizon for influenza. Curr Opin Pharmacol. 2016 Aug 25;30:106-115.
Full text

Nakamura S, Kohno S. [Anti-influenza virus agent]. [Article in Japanese] Nihon Rinsho. 2012 Apr;70(4):568-73.
Abstract

Nakano T. et al. Safety evaluation of laninamivir octanoate hydrate through analysis of adverse events reported during early post-marketing phase vigilance. Scand J Infect Dis. 2013 Jun;45(6):469-77. Epub 2013 Feb 4.
Abstract

Nguyen HT, Fry AM, Gubareva LV. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivir Ther. 2012;17(1 Pt B):159-73.
Abstract

Okoli GN. et al. Use of neuraminidase inhibitors for rapid containment of influenza: a systematic review and meta-analysis of individual and household transmission studies. PLoS One. 2014 Dec 9;9(12):e113633.
Full text

Okomo-Adhiambo M. Sheu, TG, Gubareva LV. Assays for monitoring susceptibility of influenza viruses to neuraminidase inhibitors. Influenza Other Respi Viruses 2013 Jan;7 Suppl 1:44-9.
Full text

Rossignol JF. Nitazoxanide: A first-in-class broad-spectrum antiviral agent. Antiviral Res. 2014 Aug 7;110C:94-103.
Abstract

Samson M. et al. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res. 2013 May;98(2):174-85.
Abstract

Santesso N. et al. Antivirals for influenza: a summary of a systematic review and meta-analysis of observational studies. Influenza Other Respir Viruses. 2013 Sep;7 Suppl 2:76-81.
Full text

Shan Y. et al. Recent advances in the structure-based design of neuraminidase inhibitors as antiinfluenza agents. Curr Med Chem. 2012;19(34):5885-94.
Abstract

Shin WJ, Seong BL. Recent advances in pharmacophore modeling and its application to anti-influenza drug discovery. Expert Opin Drug Discov. 2013 Apr;8(4):411-26.
Abstract

Skalickova S. et al. Perspective of Use of Antiviral Peptides against Influenza Virus. Viruses. 2015 Oct 20;7(10):5428-42.
Full text

Smith LE. et al. A systematic review of factors affecting intended and actual adherence with antiviral medication as treatment or prophylaxis in seasonal and pandemic flu. Influenza Other Respir Viruses. 2016 Jul 11.
Full text

Spanakis N. et al. A review of neuraminidase inhibitor susceptibility in influenza strains. Expert Rev Anti Infect Ther. 2014 Nov;12(11):1325-36.
Abstract

Standing JF, Tsolia M, Lutsar I. Pharmacokinetics and pharmacodynamics of oseltamivir in neonates, infants and children. Infect Disord Drug Targets. 2013 Feb;13(1):6-14.
Abstract

Tanner EJ, Kirkegaard KA, Weinberger LS. Exploiting Genetic Interference for Antiviral Therapy.PLoS Genet. 2016 May 5;12(5):e1005986.
Full text

Tashani M. et al. Oseltamivir for control of influenza at mass gatherings. Infect Disord Drug Targets. 2013 Feb;13(1):46-52.
Abstract

Toovey S et al. Post-marketing assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: an updated review. Adv Ther. 2012 Oct;29(10):826-48.
Abstract

Tsiodras S, Nikolopoulos G, Bonovas S. Antivirals used for influenza chemoprophylaxis. Curr Med Chem. 2012;19(35):5947-56.
Abstract

Vargas-Sandoval G. et al. Effectiveness and Side Effects of Oseltamivir for Influenza Treatment: A Meta-Analysis of Meta-Analysis. Value Health. 2015 Nov;18(7):A832.

Watanabe T, Kawaoka Y. Influenza virus-host interactomes as a basis for antiviral drug development. Curr Opin Virol. 2015 Oct;14:71-8.
Abstract

Wester A, Shetty AK. Peramivir injection in the treatment of acute influenza: a review of the literature. Infect Drug Resist. 2016 Aug 22;9:201-14.
Full text

Wollenhaupt M, Chandrasekaran A, Tomianovic D. The safety of oseltamivir in pregnancy: an updated review of post-marketing data. Pharmacoepidemiol Drug Saf. 2014 Oct;23(10):1035-42.
Abstract

Yang HT. et al. Translating genomic sequences into antibody efficacy and safety against influenza toward clinical trial outcomes: a case study. (Taiwan) Drug Discov Today. 2016 Jun 15. pii: S1359-6446(16)30226-4.
Abstract

Yen HL. Current and novel antiviral strategies for influenza infection. Curr Opin Virol. 2016 Jun 23;18:126-134.
Abstract

Yin J.K. et al. Oseltamivir use in adolescents and adults: clinical and economic considerations. Infect Disord Drug Targets. 2013 Feb;13(1):53-8.
Abstract

Zhao P. et al. Efficacy of Lianhuaqingwen Capsule Compared With Oseltamivir for Influenza A Virus Infection: A Meta-analysis of Randomized, Controlled Trials. Altern Ther Health Med. 2014 Mar;20(2):25-30
Abstract

Zhou X. Citations alone were enough to predict favorable conclusions in reviews of neuraminidase inhibitors. J Clin Epidemiol. 2015 Jan;68(1):87-93.
Full text